Safety of cluster specific immunotherapy with a modified high-dose house dust mite extract
Abstract
Introduction. Although the efficacy and safety of high dose hypoallergenic mite subcutaneousimmunotherapy (SCIT) using a conventional administration schedule has alreadybeen demonstrated, there is no reported experience on the safety of these extracts with clusterschedules.We wanted to determine whether the use of a cluster schedule of a hypoallergenicallergen with a high concentration of house dust mite allergens commonly used in normalpractice was safe and well-tolerated in patients with dust mite allergy. Material andMethods. Multicentre, observational, retrospective study of dust mite allergic patientstreated with a cluster schedule of SCIT (Acaroid®; Day 1: 300/300 therapeutic units,TU– Day 8: 1000/1000 TU- Day 15: 3000/3000 TU) in 23 Spanish sites. Results. Clusterschedule was used on 434 patients (40.1% children), with a total of 3256 doses (38.2% inchildren). There were 88 clinically relevant adverse reactions, 79 out of them local and 9systemic (but mild-moderate) that amounted to 2.7% of all the administered doses. All thepatients fulfilled the cluster schedule. Conclusions. Cluster schedule with high dose hypoallergenicmite-SCIT was safe and well-tolerated in routine clinical practice. Therefore, itsuse could reduce the costs and time needed to achieve the desired maintenance dose and increasecompliance
Keywords
Subcutaneous immunotherapy (SCIT); dust mites; high-dose allergoid cluster schedules; safety
Full Text: PDF
No comments:
Post a Comment